Penggunaan Prednisolon sebagai Terapi Alternatif pada Pustular Psoriasis Of Pregnancy: Sebuah Laporan Kasus
Abstract
Tujuan: Pustular Psoriasis of Pregnancy (PPP) merupakan keadaan psoriasis berat yang jarang sekali terjadi pada kehamilan dan berkaitan dengan peningkatan risiko terjadinya kelahiran prematur dan berat badan bayi rendah. Pilihan kortikosteroid sebagai terapi lini pertama masih bervariasi antara prednison oral, siklosporin, kortikosteroid topikal, hingga kalsipotriene topikal
Kasus: Kami melaporkan presentasi kasus G4P3A0 usia 34 tahun dengan PPP berulang pada usia kehamilan 8 bulan. Pasien menjalani perawatan konservatif dengan Dexametasone 2x6 mg intramuskular sebagai pematang paru janin selama 2 hari lalu dilanjutkan dengan terapi prednisolon dosis tinggi (80 mg/hari) untuk PPP. Prednisolon dipilih sebagai alternatif terapi pada kasus ini sampai pasien melahirkan.
Hasil: Bayi lahir aterm dengan APGAR skor 7 - 9. Tidak ada kelainan kongenital dan kelainan dermatologi pada janin. Keluhan kulit membaik setelah pasien melahirkan. Pengobatan prednisolon dilanjutkan sampai 2 minggu post partum dengan dosis diturunkan bertahap (50 mg/hari selama 1 minggu pertama dilanjutkan 30 mg/hari selama 1 minggu kemudian) lalu dihentikan.
Kesimpulan Penggunaan prednisolon sebagai terapi alternatif PPP pada laporan kasus ini tidak menunjukkan adanya efek samping pada ibu maupun janin.
Prednisolone as an Alternative Treatment for Pustular Psoriasis of Pregnancy: A Case Report
Abstract
Introduction: Pustular Psoriasis of Pregnancy (PPP) is a severe psoriasis condition that rarely occurs in pregnancy and is associated with an increased risk of premature birth and low birth weight. The choice of corticosteroids as a first-line therapy still varies between oral prednisone, cyclosporine, topical corticosteroids to topical calcipotriene.
Case: In this case presentation, we report a 34-year-old G4P3A0 with recurrent PPP at 8 months of gestation. The patient had conservative management with Dexametasone 2x6 mg intramuskular as fetal lung maturation for 2 days, then was continued with high dose of Prednisolone (80 mg/hari) for PPP. Prednisolone was chosen as an alternative treatment in this case until the patient gave birth.
Result:. The baby was born term with APGAR score 7-9. No congenital or dermatological problem on baby. Skin complaints resolved two months postpartum. Prednisolone was continued until 2 weeks postpartum with taped off doses (50 mg/day for the first week and 30 mg/day for the next week) and then was stopped.
Conclusion: The usage of Prednisolone as an alternative treatment for PPP pada in this case report do not show any adverse outcomes.
Key words: pustular psoriasis of pregnancy, prednisolone
Keywords
Full Text:
PDFReferences
Kondo RN, Araújo FM, Pereira AM, Lopes VC, Martins LM. Pustular psoriasis of pregnancy (impetigo herpetiformis)--case report. An Bras Dermatol. 2013;88(6 Suppl 1):186−9.
Wamalwa EW. Recurrent impetigo herpetiformis: case report. Pan Afr Med J. 2017;27:219.
Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109−15.
Cunningham FG, Leveno KJ, Dashe JS, Hoffman BL, Spong CY, Casey BM. Williams Obstetrics 26e. McGraw Hill LLC; 2022.
Samotij D, Szczęch J, Reich A. Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity. Int J Mol Sci. 2021;22(16).
Yao X, Zhang X, Peng M, Wang H, Meng Y, Chen Y. A case of impetigo herpetiformis in which termination of pregnancy was required. J Int Med Res. 2020;48(7):300060520933811.
Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical Disease Measures in Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):39−50.
Bozdag K, Ozturk S, Ermete M. A case of recurrent impetigo herpetiformis treated with systemic corticosteroids and narrowband UVB. Cutan Ocul Toxicol. 2012;31(1):67−9.
Ma N, Qin R, Qin W, Liao M, Zhao Y, Hang F, dkk. Oral immunosuppressants improve pregnancy outcomes in women with idiopathic recurrent miscarriage: A meta-analysis. J Clin Pharm Ther. 2022;47(7):870
Kieffer TE, Chin PY, Green ES, Moldenhauer LM, Prins JR, Robertson SA. Prednisolone in early pregnancy inhibits regulatory T cell generation and alters fetal and placental development in mice. Mol Hum Reprod. 2020;26(5):340−52.
DOI: http://dx.doi.org/10.24198/obgynia.v7i1.656
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.